Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to treat patients with genetically defined rare diseases characterized by high unmet medical need. The company's lead product candidate, pociredir, is an oral small molecule… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Fulcrum Therapeutics, Inc. does
In the company’s own words
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to treat patients with genetically defined rare diseases characterized by high unmet medical need. The company's lead product candidate, pociredir, is an oral small molecule designed to induce fetal hemoglobin and is currently in clinical development for sickle cell disease treatment. Fulcrum completed dosing in the PIONEER Phase 1b clinical trial evaluating pociredir in adults with sickle cell disease and is currently activating sites in an open-label extension trial to assess longer-term safety and durability. The company plans to initiate a potential registration-enabling trial in the second half of 2026 pending FDA feedback.
Beyond pociredir, Fulcrum has developed a proprietary discovery approach to identify and validate cellular drug targets that modulate gene expression to address the root causes of rare genetic diseases, with a primary focus on hematology conditions. The company presented preclinical data for FTX-6274, an oral EED inhibitor candidate, demonstrating tumor growth inhibition in prostate cancer models. Fulcrum has decided not to advance its bone marrow failure syndromes program into clinical development to focus resources on pociredir and core benign hematology programs.
Pociredir has received orphan drug designation and fast track designation from the FDA for sickle cell disease treatment. The company's intellectual property portfolio includes three issued U.S. patents related to pociredir composition of matter and methods of use, with additional pending applications expected to expire between 2039 and 2046. Fulcrum does not operate manufacturing facilities and relies on contract manufacturing organizations for production of its product candidates.
In July 2023, Fulcrum entered into an exclusive global license agreement with CAMP4 Therapeutics for rights to the DBA program, with potential milestone payments up to $70 million and royalties on net sales. The company operates without reportable segments and maintains its website at www.fulcrumtx.com. As of December 31, 2025, Fulcrum had accumulated losses of $594.3 million and reported a net loss of $74.9 million for the fiscal year.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1680581
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Fulcrum Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Fulcrum Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Fulcrum Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Fulcrum Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Fulcrum Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”